Home/Filings/4/0001209191-20-004922
4//SEC Filing

JANNEY DANIEL 4

Accession 0001209191-20-004922

CIK 0001564824other

Filed

Jan 23, 7:00 PM ET

Accepted

Jan 24, 6:24 PM ET

Size

30.2 KB

Accession

0001209191-20-004922

Insider Transaction Report

Form 4
Period: 2020-01-22
Transactions
  • Other

    Common Stock

    2020-01-22+11,53811,538 total(indirect: By LLC)
  • Other

    Common Stock

    2020-01-221,000,00010,519,200 total(indirect: See Footnote)
  • Other

    Common Stock

    2020-01-22+6,8376,837 total
  • Other

    Common Stock

    2020-01-2234,6150 total(indirect: By APNG I Management)
  • Other

    Common Stock

    2020-01-22+11,53811,538 total
  • Other

    Common Stock

    2020-01-22+34,61534,615 total(indirect: By APNG I Management)
  • Other

    Common Stock

    2020-01-22+11,53911,539 total(indirect: By Alta Bioequities, L.P.)
Transactions
  • Other

    Common Stock

    2020-01-22+6,8376,837 total
  • Other

    Common Stock

    2020-01-221,000,00010,519,200 total(indirect: See Footnote)
  • Other

    Common Stock

    2020-01-22+11,53811,538 total
  • Other

    Common Stock

    2020-01-22+34,61534,615 total(indirect: By APNG I Management)
  • Other

    Common Stock

    2020-01-2234,6150 total(indirect: By APNG I Management)
  • Other

    Common Stock

    2020-01-22+11,53811,538 total(indirect: By LLC)
  • Other

    Common Stock

    2020-01-22+11,53911,539 total(indirect: By Alta Bioequities, L.P.)
Transactions
  • Other

    Common Stock

    2020-01-2234,6150 total(indirect: By APNG I Management)
  • Other

    Common Stock

    2020-01-22+11,53911,539 total(indirect: By Alta Bioequities, L.P.)
  • Other

    Common Stock

    2020-01-221,000,00010,519,200 total(indirect: See Footnote)
  • Other

    Common Stock

    2020-01-22+11,53811,538 total
  • Other

    Common Stock

    2020-01-22+34,61534,615 total(indirect: By APNG I Management)
  • Other

    Common Stock

    2020-01-22+11,53811,538 total(indirect: By LLC)
  • Other

    Common Stock

    2020-01-22+6,8376,837 total
CHAMPSI FARAH
10% Owner
Transactions
  • Other

    Common Stock

    2020-01-22+34,61534,615 total(indirect: By APNG I Management)
  • Other

    Common Stock

    2020-01-22+11,53911,539 total(indirect: By Alta Bioequities, L.P.)
  • Other

    Common Stock

    2020-01-221,000,00010,519,200 total(indirect: See Footnote)
  • Other

    Common Stock

    2020-01-2234,6150 total(indirect: By APNG I Management)
  • Other

    Common Stock

    2020-01-22+11,53811,538 total(indirect: By LLC)
  • Other

    Common Stock

    2020-01-22+6,8376,837 total
  • Other

    Common Stock

    2020-01-22+11,53811,538 total
MORE ROBERT J
10% Owner
Transactions
  • Other

    Common Stock

    2020-01-221,000,00010,519,200 total(indirect: See Footnote)
  • Other

    Common Stock

    2020-01-22+11,53811,538 total
  • Other

    Common Stock

    2020-01-2234,6150 total(indirect: By APNG I Management)
  • Other

    Common Stock

    2020-01-22+34,61534,615 total(indirect: By APNG I Management)
  • Other

    Common Stock

    2020-01-22+11,53811,538 total(indirect: By LLC)
  • Other

    Common Stock

    2020-01-22+11,53911,539 total(indirect: By Alta Bioequities, L.P.)
  • Other

    Common Stock

    2020-01-22+6,8376,837 total
NOHRA GUY P
10% Owner
Transactions
  • Other

    Common Stock

    2020-01-22+6,8376,837 total
  • Other

    Common Stock

    2020-01-22+11,53911,539 total(indirect: By Alta Bioequities, L.P.)
  • Other

    Common Stock

    2020-01-22+34,61534,615 total(indirect: By APNG I Management)
  • Other

    Common Stock

    2020-01-22+11,53811,538 total(indirect: By LLC)
  • Other

    Common Stock

    2020-01-221,000,00010,519,200 total(indirect: See Footnote)
  • Other

    Common Stock

    2020-01-2234,6150 total(indirect: By APNG I Management)
  • Other

    Common Stock

    2020-01-22+11,53811,538 total
JANNEY DANIEL
Director10% Owner
Transactions
  • Other

    Common Stock

    2020-01-22+11,53811,538 total(indirect: By LLC)
  • Other

    Common Stock

    2020-01-2234,6150 total(indirect: By APNG I Management)
  • Other

    Common Stock

    2020-01-22+34,61534,615 total(indirect: By APNG I Management)
  • Other

    Common Stock

    2020-01-22+11,53811,538 total
  • Other

    Common Stock

    2020-01-22+11,53911,539 total(indirect: By Alta Bioequities, L.P.)
  • Other

    Common Stock

    2020-01-22+6,8376,837 total
  • Other

    Common Stock

    2020-01-221,000,00010,519,200 total(indirect: See Footnote)
Transactions
  • Other

    Common Stock

    2020-01-22+6,8376,837 total
  • Other

    Common Stock

    2020-01-22+11,53811,538 total(indirect: By LLC)
  • Other

    Common Stock

    2020-01-22+11,53911,539 total(indirect: By Alta Bioequities, L.P.)
  • Other

    Common Stock

    2020-01-2234,6150 total(indirect: By APNG I Management)
  • Other

    Common Stock

    2020-01-22+11,53811,538 total
  • Other

    Common Stock

    2020-01-221,000,00010,519,200 total(indirect: See Footnote)
  • Other

    Common Stock

    2020-01-22+34,61534,615 total(indirect: By APNG I Management)
Transactions
  • Other

    Common Stock

    2020-01-2234,6150 total(indirect: By APNG I Management)
  • Other

    Common Stock

    2020-01-22+11,53811,538 total
  • Other

    Common Stock

    2020-01-22+11,53811,538 total(indirect: By LLC)
  • Other

    Common Stock

    2020-01-22+11,53911,539 total(indirect: By Alta Bioequities, L.P.)
  • Other

    Common Stock

    2020-01-22+34,61534,615 total(indirect: By APNG I Management)
  • Other

    Common Stock

    2020-01-221,000,00010,519,200 total(indirect: See Footnote)
  • Other

    Common Stock

    2020-01-22+6,8376,837 total
Footnotes (9)
  • [F1]Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Alta Partners NextGen Fund I L.P. ("APNG I"), without consideration, to its general partner and limited partners.
  • [F2]Consists of 2,557,377 shares held of record by APNG I and 7,961,823 shares held of record by Alta Partners VIII, L.P. ("Alta VIII").
  • [F3]The shares directly held by Alta VIII are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their respective pecuniary interests therein.
  • [F4]The shares directly held by APNG I are indirectly held by Alta Partners NextGen Fund I Management, LLC ("APNG I Management"), which is the general partner of APNG I. The individual managing directors of APNG I Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG I Management exercise sole voting and investment control with respect to the shares held by APNG I. The individual managing directors of APNG I Management disclaim beneficial ownership of all shares held by APNG I, except to the extent of their respective pecuniary interests therein.
  • [F5]Represents a pro-rata in-kind distribution of Common Stock of the Issuer by APNG I Management, without consideration, to its members.
  • [F6]Represents the acquisition of the shares of Common Stock of the Issuer by Robert J. More in connection with the pro-rata distribution described in footnote (5) herein.
  • [F7]Represents the acquisition of the shares of Common Stock of the Issuer by Hudson Capital, LLC, a limited liability company of which Peter A. Hudson is the managing member, in connection with the pro-rata distribution described in footnote (5) herein. Mr. Hudson disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
  • [F8]Represents the acquisition of the shares of Common Stock of the Issuer by Alta Bioequities, L.P. in connection with the pro-rata distribution described in footnote (5) herein. Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. Daniel Janney is the Managing Director of Alta Bioequities Management, LLC. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
  • [F9]Represents the acquisition of the shares of Common Stock of the Issuer by Guy P. Nohra in connection with the pro-rata distribution described in footnote (1) herein.

Issuer

Allakos Inc.

CIK 0001564824

Entity typeother

Related Parties

1
  • filerCIK 0001198325

Filing Metadata

Form type
4
Filed
Jan 23, 7:00 PM ET
Accepted
Jan 24, 6:24 PM ET
Size
30.2 KB